The purpose of the assessment is to evaluate canagliflozin ‘Invokana’ and its use as a treatment of type 2 diabetes mellitus.
Final version of the assessment was published in February 2014
Below is the documentation provided by the Joint Assessment authoring team:
Canagliflozin for the treatment of diabetes mellitus_Rapid REA_Final_Feb 2014
This website was produced under the Third EU Health Programme through a service contract with the European Health and Digital Executive Agency (HaDEA) acting under the mandate from the European Commission. The information and views set out in this website are those of the author(s) and do not necessarily reflect the official opinion of the Commission/Executive Agency. The Commission/Executive Agency do not guarantee the accuracy of the data included in this website. Neither the Commission/Executive Agency nor any person acting on the Commission’s/Executive Agency’s behalf may be held responsible for the use which may be made of the information contained therein.
©2021 EUnetHTA All rights reserved.
